Pediatric Pharmacy Specialty Review Course for Recertification, Core Therapeutic Modules + RECERT EXAMS Package
(Cert # L229268)

Teaser: This online course will help you earn BCPPS recertification credit. With this course, get comprehensive, practical guidance, with a variety of complex cases, including references for further study.

Tag: Certifications; Pediatric

ACPE Numbers: Various – see listing below
Pre-Sale Date: 08/31/2022
Content Release Date: 09/21/2022
Expiration Date: 09/19/2023
Activity Type: Application-based
CE Credits: 19.5 (BPS and ACPE) contact hours
Activity Fee: $475 (ASHP member); $675 (non-member)

Accreditation for Pharmacists
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Target Audience
These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in pediatric pharmacy.

Activity Overview
This course is intended for BCPPSs in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS) to provide an overview of recent standards and guidelines that specialists should be familiar with in practice. The course uses a case-based approach to discuss patient care issues. In this series, faculty will:
- Review pertinent clinical topics and practice skills
- List valuable resources for further self-study

This online course consists of 14 activities (see tables below) and provides up to 19.5 contact hours of continuing pharmacy education credit and/or recertification credit.

Recertification Credit*
Board certified pharmacists are eligible to receive up to 19.5 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

This course is not intended for those preparing to take the BPS Pediatric Pharmacy Specialty Examination for Certification. To prepare for the examination, please see courses here: [http://elearning.ashp.org/catalog/pediatric-review](http://elearning.ashp.org/catalog/pediatric-review)
These activities are part of the ASHP professional development program for BCPPS recertification approved by the BPS.

* Please note: Review Course for Recertification may only be completed for recertification credit up to two times, in nonconsecutive years, during the 7-year recertification cycle.

<table>
<thead>
<tr>
<th>Learning Activity</th>
<th>ACPE Number</th>
<th>Contact Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complex Case: Deep Vein Thrombosis and Metabolic Syndrome</td>
<td>0204-0000-22-620-H01-P</td>
<td>1.50 ACPE</td>
</tr>
<tr>
<td>Complex Case: Diabetic Ketoacidosis</td>
<td>0204-0000-22-621-H01-P</td>
<td>1.50 ACPE</td>
</tr>
<tr>
<td>Complex Case: Acute Asthma</td>
<td>0204-0000-22-622-H01-P</td>
<td>1.50 ACPE</td>
</tr>
<tr>
<td>Complex Case: Pneumonia and Septic Shock</td>
<td>0204-0000-22-623-H01-P</td>
<td>1.50 ACPE</td>
</tr>
<tr>
<td>Recertification Assessment Group 1 (79% passing score required)</td>
<td></td>
<td>6.0 BPS</td>
</tr>
<tr>
<td>Complex Case: Acute Lymphoblastic Leukemia with Tumor Lysis Syndrome</td>
<td>0204-0000-22-624-H01-P</td>
<td>1.50 ACPE</td>
</tr>
<tr>
<td>Regulatory and IRB Considerations</td>
<td>0204-0000-22-625-H03-P</td>
<td>0.50 ACPE</td>
</tr>
<tr>
<td>Complex Case: Sickle Cell Disease with Vaso-Occlusive Crisis</td>
<td>0204-0000-22-626-H01-P</td>
<td>1.50 ACPE</td>
</tr>
<tr>
<td>Medication Error and Practice Management</td>
<td>0204-0000-22-627-H05-P</td>
<td>1.50 ACPE</td>
</tr>
<tr>
<td>Recertification Assessment Group 2 (81% passing score required)</td>
<td></td>
<td>5.0 BPS</td>
</tr>
<tr>
<td>Complex Case: Neonatal Sepsis</td>
<td>0204-0000-22-628-H01-P</td>
<td>1.50 ACPE</td>
</tr>
<tr>
<td>Complex Case: Status Epilepticus and Cardiopulmonary Resuscitation</td>
<td>0204-0000-22-629-H01-P</td>
<td>1.50 ACPE</td>
</tr>
<tr>
<td>Statistics, Evidence-Based Medicine, and Clinical Trial Design</td>
<td>0204-0000-21-985-H04-P</td>
<td>2.00 ACPE</td>
</tr>
<tr>
<td>Recertification Assessment Group 3 (73% passing score required)</td>
<td></td>
<td>5.0 BPS</td>
</tr>
</tbody>
</table>

**Learning Objectives**

After participating in this CPE activity, learners should be able to:

**Complex Case: Deep Vein Thrombosis and Metabolic Syndrome**

**ACPE #: 0204-0000-22-620-H01-P**

- Develop appropriate treatment and monitoring plans for a complex pediatric patient with multiple conditions, including deep vein thrombosis, type 2 diabetes mellitus, dyslipidemia, and hypertension.
- Identify resources and treatment options for sexually transmitted infections.
- Select appropriate monitoring considerations of anticoagulation medications.
- Recognize the impact of pharmacogenomic differences on warfarin therapy.

**Complex Case: Diabetic Ketoacidosis**

**ACPE #: 0204-0000-22-621-H01-P**

- Develop appropriate treatment and monitoring plans for a complex pediatric patient with multiple conditions, including diabetic ketoacidosis, type 1 diabetes mellitus, and urinary tract infection.
- Calculate maintenance and replacement fluid requirements and urine output.
- Identify factors affecting medication adherence.
- Recommend appropriate dosing of insulin based on patient age and weight.
- Select an effective method of delivery for insulin.
Complex Case: Acute Asthma
ACPE #: 0204-0000-22-622-H01-P

- Develop appropriate treatment and monitoring plans for a complex pediatric patient with multiple conditions, including acute and chronic asthma, ADHD, acne and GERD.
- Evaluate essential components of social history, including smoke exposure and home environment.
- Formulate a plan to address barriers to patient education and adherence, including age, language, cultural considerations, and inhaler technique.
- Describe the impact of age on classification and management of asthma.
- Assess available resources to improve access to medications, including patient assistance programs.

Complex Case: Pneumonia and Septic Shock
ACPE #: 0204-0000-22-623-H01-P

- Develop appropriate treatment and monitoring plans for a complex pediatric patient with multiple conditions, including pneumonia, septic shock, and acute kidney injury.
- Calculate creatinine clearance, fluid requirements, and urine output in pediatric patients.
- Apply scoring systems to assess pediatric patients.
- Select appropriate dosing for medications based on renal dysfunction and/or replacement modalities.
- Differentiate vital signs between stable and critically-ill pediatric patients.

Complex Case: Acute Lymphoblastic Leukemia with Tumor Lysis Syndrome
ACPE #: 0204-0000-22-624-H01-P

- Develop appropriate treatment and monitoring plans for a complex pediatric patient with multiple conditions, including acute lymphoblastic leukemia (ALL), tumor lysis syndrome, febrile neutropenia, invasive aspergillosis infection, and Clostridium difficile infection.
- Select appropriate medication dose modifications related to hepatic impairment.

Complex Case: Sickle Cell Disease with Vaso-Occlusive Crisis
ACPE #: 0204-0000-22-626-H01-P

- Develop appropriate treatment and monitoring plans for a complex pediatric patient with multiple conditions, including a vaso-occlusive crisis, cellulitis, constipation, and need for immunizations.
- Select most appropriate patient controlled analgesia regimen based on vaso-occlusive crisis severity.
- Apply pharmacodynamic principles when selecting appropriate antibiotic regimens.
- Identify required immunizations for adolescents, including patients with risk factors for vaccine-preventable diseases.

Regulatory and IRB Considerations
ACPE #: 0204-0000-22-625-H03-P

- Identify appropriate off-label use of medications in the pediatric population.
- Recognize IRB requirements for documentation of clinical studies
- List characteristics of patients who require informed assent/consent.
- Recognize federal legislation relevant to the use of medications in pediatric patients.
Medication Error and Practice Management
ACPE #: 0204-0000-22-627-H05-P
- Incorporate position statements, white papers, national guidelines from recognized regulatory organizations into institutional policies and procedures related to:
- Medication reconciliation
- Appropriate drug preparation and delivery (e.g., extemporaneous compounding and standardized concentrations)
- Selection of appropriate equipment/technology and decision support.
- Adverse drug event monitoring and reporting, or
- Metrics for evaluating quality of pediatric pharmacy services.

Complex Case: Neonatal Sepsis
ACPE #: 0204-0000-22-628-H01-P
- Develop appropriate treatment and monitoring plans for a complex neonatal patient with multiple conditions, including patent ductus arteriosus, apnea of prematurity, early and late onset sepsis, and necrotizing enterocolitis.
- Evaluate the clinical and therapeutic implications of placental transfer of medications.
- Identify age-specific pharmacokinetic differences among neonates, infants, children, and adolescents.
- Apply FDA alerts for adverse drug events and drug-drug interactions into clinical practice.
- Identify characteristics that facilitate transfer of medications into the breast milk.

Complex Case: Status Epilepticus and Cardiopulmonary Resuscitation
ACPE #: 0204-0000-22-629-H01-P
- Develop appropriate treatment and monitoring plans for a complex pediatric patient with multiple conditions and needs, including status epilepticus, cardiopulmonary resuscitation, and sedation/analgesia.
- Differentiate treatment options in cardiopulmonary arrest based upon patient presentation.
- Select the appropriate dose and route of administration for medications.
- Assess the need and processes for reporting adverse drug events.
- Identify cultural considerations related to treatment and counseling of the pediatric population.
- Distinguish between the four preceptor roles.

Statistics, Evidence-Based Medicine, and Clinical Trial Design
ACPE #: 0204-0000-21-985-H04-P
- Interpret biomedical literature with regard to study design, methodology, statistical analysis, and significance and applicability of reported data and conclusions.
- Explain the use of evidence-based treatment guidelines and protocols.
- Summarize key points from the most current pharmacy practice literature.
CORE THERAPEUTIC MODULES
The Core Therapeutic Modules Review Package consists of 3 activities in which faculty review clinical topics and practice skills using a case-based approach. The activities are designed to assist the learner in identifying knowledge gaps in preparation for a pharmacy specialty board examination. In addition to a recorded presentation, each activity includes links to resources for further self-study and a practice test developed in the same format and rigor as the specialty exam.

<table>
<thead>
<tr>
<th>Learning Activity</th>
<th>ACPE Number</th>
<th>Contact Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Select Topics in Pediatric Cardiovascular Disease</td>
<td>0204-0000-22-630-H01-P</td>
<td>1.00 ACPE</td>
</tr>
<tr>
<td>Select Topics in Pediatric Infectious Diseases Part 1</td>
<td>0204-0000-22-631-H01-P</td>
<td>1.00 ACPE</td>
</tr>
<tr>
<td>Select Topics in Pediatric Neurology Part 2 - Focus on Seizures</td>
<td>0204-0000-22-632-H01-P</td>
<td>1.00 ACPE</td>
</tr>
<tr>
<td>Recertification Assessment (TBD% passing score required)</td>
<td>0204-0000-22-633-H01-P</td>
<td>3.0 BPS</td>
</tr>
</tbody>
</table>

Learning Objectives
After participating in these CPE activities, learners should be able to:

Select Topics in Pediatric Cardiovascular Disease
ACPE #: 0204-0000-22-630-H01-P
- Interpret signs, symptoms and diagnostic tests in a pediatric patient with congenital heart disease (specifically VSD, ASD, TOF, coarctation of aorta, and hypoplastic left heart) or Kawasaki disease
- Identify drug-related problems, including drug interactions.
- Develop the most appropriate therapy and monitoring plans based on patient-specific information and the most current guidelines.
- Use PALS to determine appropriate therapy for bradycardia and tachycardia.

Select Topics in Pediatric Infectious Diseases Part 1
ACPE #: 0204-0000-22-631-H01-P
- Develop treatment and monitoring plans based on patient-specific information and the most current guidelines for a well-appearing febrile infant.
- Develop treatment and monitoring plans based on patient-specific information and the most current guidelines for a pediatric patient with otitis media
- Develop treatment and monitoring plans based on patient-specific information and the most current guidelines for a pediatric patient with bronchiolitis
- Develop treatment and monitoring plans based on patient-specific information and the most current guidelines for a pediatric patient with tuberculosis
- Develop treatment and monitoring plans based on patient-specific information and the most current guidelines for a pediatric patient with meningitis
- Develop treatment and monitoring plans based on patient-specific information and the most current guidelines for a pediatric patient with pneumonia

Copyright © 2022, American Society of Health-System Pharmacists. All rights reserved.
Select Topics in Pediatric Neurology Part 2 - Focus on Seizures
ACPE #: 0204-0000-22-632-H01-P

- Develop treatment and monitoring plans based on patient-specific information and the most current guidelines for a pediatric patient with febrile seizures, neonatal seizures, infantile spasms, absence seizures, and Lennox-Gastaut syndrome.
- Evaluate patients for drug-related problems.
- Identify appropriate modifications of patient-specific treatment plans based on follow up assessment.

Faculty
Teia Brandenburg, PharmD, BCPPS
Clinical Pharmacist – Child Neurology
University of Kentucky Healthcare
Lexington, Kentucky

Kaitlin Hughes, PharmD, BCPPS
Clinical Pharmacist Pediatric Critical Care
Riley Hospital for Children at IU Health
Indianapolis, Indiana

Peter N. Johnson, PharmD, BCPS, BCPS, FCCM, FPPAG
Professor of Pharmacy Practice
University of Oklahoma College of Pharmacy
Oklahoma City, Oklahoma

Michelle Kussin, PharmD, BCOP
Clinical Pharmacist, Pediatric Infectious Diseases
Riley Hospital for Children at Indiana University Health
Indianapolis, Indiana

Kevin Lonabaugh, PharmD, BCACP, AAHIVP, AE-C
Clinical Pharmacist - Pediatric Ambulatory Care
University of Virginia Children’s Hospital
Charlottesville, Virginia

Mya Merrow, PharmD, BCOP
Pediatric Oncology Clinical Pharmacist
Children’s Hospital Colorado
Aurora, Colorado

Rachel S. Meyers, PharmD, BCPPS, BCPS, FPPAG
Clinical Associate Professor

Ernest Mario School of Pharmacy Rutgers, The State University of New Jersey

Jamie L. Miller, PharmD, BCPPS, BCPS, FPPAG*
Professor
University of Oklahoma College of Pharmacy
Oklahoma City, Oklahoma

Jill Morgan, PharmD, BCPPS, BCPS
Professor and Chair
University of Maryland School of Pharmacy
Baltimore, Maryland

Ashley Nebbia, PharmD, BCCPS
Emergency Medicine Clinical Pharmacist
Golisano Children’s Hospital of SW Florida
Fort Myers, Florida

Jennifer Thackray, PharmD, BCPPS, BCPS*
Pediatric Oncology Clinical Pharmacy Specialist
Memorial Sloan Kettering Cancer Center
New York

Lisa Thames, PharmD, BCPS
Assistant Director, Inpatient Pharmacy Services
UF Health Shands Hospital
Gainesville, Florida

*Content matter experts

Reviewers
Michelle Abalos, PharmD
Susan R. Dombrowski, M.S., R.Ph.
Kristi Hofer, PharmD

Copyright © 2022, American Society of Health-System Pharmacists. All rights reserved.
Materials for this course will release 09/21/2022

Field Testers
Hakeem Abayomi, BSc, PharmD, BCPS, BCPPS, BCIDP
Leanna Barker, PharmD, BCPPS
Emily Barlow, PharmD, BCPPS
Mei Bell, PharmD, BCPS
Jessica Bergsbaken, PharmD, BCPPS
Monica Bogenschutz, PharmD, BCPS, BCPPS
Olivia Brandner, PharmD, BCPPS
Amber Brax, PharmD, BCPPS
Jordan Burdine, PharmD, MBA, BCPPS
Jeff Butler, PharmD, BCPPS
Melissa Cook, PharmD, BCPPS
Aaron Cooper, PharmD, BCPPS
Jesse Cramer, PharmD, BCPPS
Mackenzie DeVine, PharmD, BCPPS
Darrin Dillingham, PharmD, BCPPS
Charisa Flaherty, PharmD, BCPPS
Jessica Frye, PharmD, BCPPS
Sarah Hale, PharmD, BCPPS, BCPS
Samantha Hanna, PharmD, BCPPS
Tina Hellauer, PharmD, BCPPS
Amy Holmes, PharmD, BCPPS, FPPA
Katie Hughes, PharmD, BCPPS
Jin Kim, PharmD, BCPPS
Ashley Lange, PharmD, BCPPS
Ann Lieb, PharmD, BCPPS
Kristin Luckeroth, PharmD, BCPPS
Julie Miller, PharmD, BCPPS
Macy Miller, PharmD, BCPPS
Erin Munsel, PharmD, BCPPS
Ashley Nebbia, PharmD, BCPPS
Lane Nguyen, PharmD, BCPPS
Seema Patel, PharmD, MMI, BCPPS, APhA
Tasha Porter, PharmD, BCPPS
Allison Provine, PharmD, BCPS, BCPPS
Karla Resendiz, PharmD, BCPPS, BCCCP
Anna Simmont, PharmD, BCPS, BCPPS
Tara Smith, PharmD, BCPPS
Sylvia Stoffella, PharmD, BCPPS
Jon Swanson, PharmD, BCPPS
Susan Villegas, PharmD, BCPPS
Aspen Wall, PharmD, BCPPS
Lynn Warner, PharmD, BCPPS
Stephanie Weightman, PharmD, BCPS, BCPPS

Disclosures
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.

No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company.

Methods and CE Requirements
Activities can be completed in any order. Each activity consists of audio, video, and/or PDFs and evaluations. Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity.

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

System Technical Requirements
Learning activities are delivered via your Web browser and Acrobat PDF. For all activities you should have a basic comfort level using a computer and navigating web sites.
View the minimum technical and system requirements for learning activities.

Development
These activities were developed by ASHP.